Regulatory and Safety Aspects of Cell and Gene Therapy

Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.

    Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy

    November 21-22, 2024

    11th World Congress on Epigenetics and Chromosome

    Dubai, UAE

    Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in